AllianceBernstein
DNTH icon

AllianceBernstein’s Dianthus Therapeutics DNTH Stock Holding History

AllianceBernstein’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$70M Sell
834,150
-91,921
-10% -$8.03M 0.02% 511
2026
Q1 		$38.2M Buy
926,071
+91,688
+11% +$5.31M 0.01% 685
2025
Q4 		$34.4M Sell
834,383
-18,001
-2% -$698K 0.01% 741
2025
Q3 		$33.5M Sell
852,384
-322,438
-27% -$8.24M 0.01% 739
2025
Q2 		$21.9M Buy
1,174,822
+149,200
+15% +$2.8M 0.01% 872
2025
Q1 		$18.6M Sell
1,025,622
-134,154
-12% -$2.96M 0.01% 905
2024
Q4 		$25.3M Buy
1,159,776
+136,633
+13% +$3.51M 0.01% 833
2024
Q3 		$28M Buy
1,023,143
+998,133
+3,991% +$27.8M 0.01% 787
2024
Q2 		$647K Buy
+25,010
New +$601K ﹤0.01% 2522
2022
Q2 		– Sell
-2,238
Closed -$104K – 3293
2022
Q1 		$104K Hold
2,238
– – ﹤0.01% 3110
2021
Q4 		$159K Hold
2,238
– – ﹤0.01% 3127
2021
Q3 		$261K Sell
2,238
-156
-7% -$18.2K ﹤0.01% 3000
2021
Q2 		$375K Buy
2,394
+250
+12% +$45.9K ﹤0.01% 2930
2021
Q1 		$406K Sell
2,144
-287
-12% -$48.3K ﹤0.01% 2763
2020
Q4 		$305K Hold
2,431
– – ﹤0.01% 2845
2020
Q3 		$265K Hold
2,431
– – ﹤0.01% 2864
2020
Q2 		$292K Buy
2,431
+887
+57% +$125K ﹤0.01% 2883
2020
Q1 		$155K Buy
1,544
+569
+58% +$105K ﹤0.01% 2857
2019
Q4 		$236K Buy
975
+37
+4% +$6.91K ﹤0.01% 2861
2019
Q3 		$154K Buy
938
+182
+24% +$34.6K ﹤0.01% 3002
2019
Q2 		$178K Buy
+756
New +$187K ﹤0.01% 2994

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

AllianceBernstein's DNTH Position: Q2 2026 in Review

AllianceBernstein reduced its Dianthus Therapeutics (DNTH) stake by 9.9% in Q2 2026, selling an estimated $8.03M and leaving 834,150 shares worth $70M. The position accounts for 0.02% of the portfolio, ranked #511.

AllianceBernstein first reported a position in DNTH in Q2 2019 and has held it in 21 quarters since. 268 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • AllianceBernstein held 834,150 shares of Dianthus Therapeutics worth $70M as of Q2 2026.
  • AllianceBernstein sold 91,921 Dianthus Therapeutics shares in Q2 2026, an estimated $8.03M.
  • Dianthus Therapeutics made up 0.02% of AllianceBernstein's portfolio in Q2 2026, its #511 holding.
  • AllianceBernstein first reported a position in Dianthus Therapeutics in Q2 2019 and has held it in 21 quarters since.
  • 268 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.